Document is current
Any future updates will be listed below
-
Authors
Kumar, Amrendra
Ramani, Vijay
Bharti, Vijaya
de Lima Bellan, Daniel
Saleh, Nabil
Uzhachenko, Roman
Shen, Chengli
Arteaga, Carlos
Richmond, Ann
Reddy, Sangeetha M
Vilgelm, Anna https://orcid.org/0000-0002-4446-913X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04360941 at ClinicalTrials.govnct03147287 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct03280563 at ClinicalTrials.govDocuments that mention this clinical trial
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
https://doi.org/10.1200/jco.23.01940
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
https://doi.org/10.1136/esmoopen-2018-000368
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.
https://doi.org/10.1200/jco.2023.41.16_suppl.1059
nct04169074 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
nct04272645 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct04220892 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct04118036 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct03997448 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct02779751 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct04088032 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
https://doi.org/10.1136/jitc-2021-002597
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
https://doi.org/10.1136/esmoopen-2018-000368
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct02791334 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct03294694 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct02978716 at ClinicalTrials.govDocuments that mention this clinical trial
939 Augmentation of CD8 T cell memory via CDK4/6 inhibition can be sequentially combined with PD-1 blockade to avoid toxicities
https://doi.org/10.1136/jitc-2022-sitc2022.0939
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
https://doi.org/10.1136/jitc-2024-010430
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
nct02779751 at ClinicalTrials.govDocuments that mention this clinical trial
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
https://doi.org/10.1136/jitc-2021-002597
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
https://doi.org/10.1136/esmoopen-2018-000368
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
https://doi.org/10.1136/jitc-2022-006019
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (IIDRP-16-001)
U.S. Department of Veterans Affairs (5101BX000196-04)
U.S. Department of Veterans Affairs (Senior Research Career Scientist Award)
National Institutes of Health (CA116021)
National Institutes of Health (CA116021-S1)
National Institutes of Health (CA34590)
National Institutes of Health (P30CA142543)
National Institutes of Health (P30CA68485)
National Institutes of Health (P50CA098131)
National Institutes of Health (R37CA233770)
Cancer Prevention and Research Institute of Texas (RR190020)
U.S. Department of Defense (W81XWH2210019)
University of Texas Southwestern Medical Center (Disease Oriented Clinical Scholar Award)
- License Information
